

## CORPORATE PROFILE


AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products as well as alternative sources of energy. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe to be setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living, all while respecting the environment.

5 Rockefeller Plaza  
20th Floor  
New York, NY 10111  
Phone: (212) 751-0001  
<http://www.aximbiotech.com>  
[Info@aximbiotech.com](mailto:Info@aximbiotech.com)

Grayling  
101 Avenue of the Americas  
8th Floor  
New York, NY 10013  
(646) 284 9474  
[shiwei.yin@grayling.com](mailto:shiwei.yin@grayling.com)  
[lucia.domville@grayling.com](mailto:lucia.domville@grayling.com)

## STOCK PERFORMANCE

Symbol	AXIM
Exchange	OTCQB
Market Cap.	447.43m
52 Week Range	4.45 - 16.245
Close	8.29
Volume	34
Shares Outstanding	54,564,441
As of Jan 18, 2018 4:45 pm	



## MANAGEMENT TEAM

**Dr. George E. Anastassov** – Chief Executive Officer

**Dr. Philip. A. Van Damme** – Chief Scientific/Medical Officer

**Lekhram Changoer** – Chief Technology Officer

## RECENT HEADLINES

[Jan 4, 2018 - AXIM Biotech Attends Biotech Showcase Conference in San Francisco](#)

[Dec 13, 2017 - AXIM Biotech Advances Programs Through Traditional Biotech Pathways, Positive Meeting with FDA -- SECFilings.com](#)

[Dec 13, 2017 - Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain](#)

[Dec 12, 2017 - AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission](#)

[Dec 11, 2017 - Alternate Health's Investor Webcast And Presentation Now Available For On-Demand Viewing At VirtualInvestorConferences.com](#)